Vaccines for the Immunotherapy of Prostate Cancer

  • Boris Minev
  • Michael L. Salgaller
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in men in North America (1). Although locally confined disease is treatable, recurrent and metastasized prostate cancer is essentially incurable. Androgen ablation therapy often successfully, if temporarily, impacts the progression of advanced disease, as some prostate cancer cells are androgen-responsive (2–4). However, the majority of patients inevitably progress to incurable, androgen-independent disease (2,5– 8). In addition to the acquisition of hormone refractivity, tumor heterogeneity in prostate cancer is also a major problem in the clinical management of this disease. Prostate tumors have many different populations of cancer cells expressing a variety of tumor-associated antigens (TAAs). In addition, the progression of prostate cancer from the hormone-naive primary to an increasingly androgen-independent metastatic stage is associated with a number of molecular and genetic changes affecting the expression of specific TAAs on the cell surface. The challenge—not necessarily unique to prostate cancer—is that, in order to effectively treat the very heterogeneic prostate cancers, it is critical to identify novel markers and therapeutic targets in advanced prostate cancer and androgen-independent disease. Ideal targets for prostate cancer immunotherapy would include proteins that are: (a) highly expressed in metastatic prostate cancer cells; (b) not expressed, or expressed at very low level in normal tissues; (c) accessible to therapeutic modalities at the cancer cell surface; (d) not modulated by androgen. In the realm of prostate cancer, a number of promising immunotherapy targets have been identified, and are in various stages of preclinical development or clinical trials (9–17).


Prostate Cancer Advanced Prostate Cancer Metastatic Prostate Cancer Recombinant Vaccinia Virus Prostate Stem Cell Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51:15–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Myers C, Cooper M, Stein C, et al. Suramin: a novel growth factor antagonist with activity in hormonerefractory metastatic prostate cancer. J Clin Oncol 1992; 10:881–889.PubMedGoogle Scholar
  3. 3.
    Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997; 15:382–388.PubMedGoogle Scholar
  4. 4.
    DiPaola RS. Approaches to the treatment of patients with hormone-sensitive prostate cancer. Semin Oncol 1999; 26(5 Suppl 17):24–27.PubMedGoogle Scholar
  5. 5.
    Cher ML, Shinohara K, Breslin S, Vapnek J, Carroll PR. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Br J Urol 1995; 75:771–777.PubMedCrossRefGoogle Scholar
  6. 6.
    Newling DWW. New strategies for the treatment of hormone-independent prostate cancer. Prostate cancer and prostatic diseases. 2000; 3:290–295.PubMedCrossRefGoogle Scholar
  7. 7.
    Vogelzang NJ. One hundred thirteen men with hormone-refractory prostate cancer died today. J Clin Oncol 1996; 14:1753–1755.PubMedGoogle Scholar
  8. 8.
    Murphy GP. Review of phase II hormone refractory prostate cancer trials. Urology 1999; 54(Suppl 6A):19–21.PubMedCrossRefGoogle Scholar
  9. 9.
    Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277:955–959.PubMedCrossRefGoogle Scholar
  10. 10.
    Hubert RS, Vivanco I, Chen E, et al. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Acad Sci USA 1999; 96:14523–14528.CrossRefGoogle Scholar
  11. 11.
    Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002; 62:2546–2553.PubMedGoogle Scholar
  12. 12.
    Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998; 4: 295–302.PubMedGoogle Scholar
  13. 13.
    Xu J, Kalos M, Stolk JA, et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res 2001; 61:1563–1568.PubMedGoogle Scholar
  14. 14.
    Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001; 61:5974–5978.PubMedGoogle Scholar
  15. 15.
    Salgaller ML. Prostate cancer immunotherapy at the dawn of the new millennium. Expert Opin in Investig Drugs 2000; 9:1217–1229.CrossRefGoogle Scholar
  16. 16.
    Salgaller ML. Peptides in prostate cancer. In: Kast WM, ed. Peptide-based cancer vaccines. Georgetown, TX: Landes Bioscience, 2000; 10:155–171.Google Scholar
  17. 17.
    Zhou Y, Toth M, Hamman MS, et al. Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line. Biochem Biophys Res Commun 2002; 290:830–838.PubMedCrossRefGoogle Scholar
  18. 18.
    Eaton JD, Perry MJ, Nicholson S, et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 2002; 89:19–26.PubMedCrossRefGoogle Scholar
  19. 19.
    Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399–415.PubMedCrossRefGoogle Scholar
  20. 20.
    Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95:13141–13146.PubMedCrossRefGoogle Scholar
  21. 21.
    Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57:1537–1546.PubMedGoogle Scholar
  22. 22.
    Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000; 12:571–575.PubMedCrossRefGoogle Scholar
  23. 23.
    Simons JW, Mikhak B. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Semin Oncol 1998; 25:661–676.PubMedGoogle Scholar
  24. 24.
    Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236:1229–1237.PubMedCrossRefGoogle Scholar
  25. 25.
    Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol 1998; 68:122–138.PubMedCrossRefGoogle Scholar
  26. 26.
    Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59:5160–5168.PubMedGoogle Scholar
  27. 27.
    Simons J, Nelson W, Nemunaitis J, et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002; 2:183a.Google Scholar
  28. 28.
    Dummer R. GVAX (Cell Genesys). Curr Opin Investig Drugs 2001; 2:844–848.PubMedGoogle Scholar
  29. 29.
    Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787–791.PubMedCrossRefGoogle Scholar
  30. 30.
    Wymenga LF, Wisman GB, Veenstra R, Ruiters MH, Mensink HJ. Telomerase activity in needle biopsies from prostate cancer and benign prostates. Eur J Clin Invest 2000; 30:330–335.PubMedCrossRefGoogle Scholar
  31. 31.
    Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000; 97:4796–4801.PubMedCrossRefGoogle Scholar
  32. 32.
    Vonderheide RH, Schultze JL, Anderson KS, et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001; 61:8366–8370.PubMedGoogle Scholar
  33. 33.
    Lev A, Denkberg G, Cohen CJ, et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 2002; 62:3184–3194PubMedGoogle Scholar
  34. 34.
    Hrouda D, Dalgleish AG. Gene therapy for prostate cancer. Gene Ther 1996; 3:845–852.PubMedGoogle Scholar
  35. 35.
    Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141:1076–1083.PubMedGoogle Scholar
  36. 36.
    Gao X, Porter AT, Grignon DJ, Pontes JE, Honn KV. Diagnostic and prognostic markers for human prostate cancer. Prostate 1997; 31:264–281.PubMedCrossRefGoogle Scholar
  37. 37.
    Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H. Influence of prostatespecific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 1998; 73:401–406.PubMedCrossRefGoogle Scholar
  38. 38.
    Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7:927–936.PubMedGoogle Scholar
  39. 39.
    Su ZZ, Lin J, Shen R, Fisher PE, Goldstein NI, Fisher PB. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc Natl Acad Sci USA 1996; 93:7252–7257.PubMedCrossRefGoogle Scholar
  40. 40.
    Gutman E, Sproul E, Gutman A. Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1936; 28:485–486.Google Scholar
  41. 41.
    Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAIl, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268:884–886.PubMedCrossRefGoogle Scholar
  42. 42.
    McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59:4291–4296.PubMedGoogle Scholar
  43. 43.
    Nan a G, Heath KE, Reeves HL, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001; 294:2563–2566Google Scholar
  44. 44.
    Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002; 62:2546–2553.PubMedGoogle Scholar
  45. 45.
    Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95:1735–1740.PubMedCrossRefGoogle Scholar
  46. 46.
    Dannull J, Diener PA, Prikler L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000; 60:5522–5528.PubMedGoogle Scholar
  47. 47.
    Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: Defining the target. J Natl Cancer Inst 1996; 88:1623–1634.PubMedCrossRefGoogle Scholar
  48. 48.
    Dawson NA. Response criteria in prostatic carcinoma. Semin Oncol 1999; 26:174–184.PubMedGoogle Scholar
  49. 49.
    Xue BH, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997; 30:73–78.PubMedCrossRefGoogle Scholar
  50. 50.
    Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000; 43:88–100.PubMedCrossRefGoogle Scholar
  51. 51.
    Alexander RB, Brady F, Leffell MS, Tsai V, Celis E. Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology 1998; 51:150–157.PubMedCrossRefGoogle Scholar
  52. 52.
    Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998; 161:3186–3194.PubMedGoogle Scholar
  53. 53.
    Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic T lymphocytes snecific for nentides derived from prostate-specific antigen. J Natl Cancer Inst 1997; 89:293–300.PubMedCrossRefGoogle Scholar
  54. 54.
    Moss B, Flexner C. Vaccinia virus expression vectors. Annu Rev Immunol 1987; 5:305–324.PubMedCrossRefGoogle Scholar
  55. 55.
    Hodge JW, Schlom J, Donohue SJ, et al. A recombinant vaccinia virus expressing human prostatespecific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 1995; 63: 231–237.PubMedCrossRefGoogle Scholar
  56. 56.
    Sanda MG, Smith DC, Charles LG, et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 1999; 53:260–266.PubMedCrossRefGoogle Scholar
  57. 57.
    Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostatespecific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6:1632–1638.PubMedGoogle Scholar
  58. 58.
    Hwang C, Sanda MG. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapv. Curr Opin Molec Ther 1999; 1:471–479.Google Scholar
  59. 59.
    Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18:3964–3973PubMedGoogle Scholar
  60. 60.
    Schirrmacher V, Ahlert T, Probstle T, et al. Immunization with virus-modified tumor cells. Semin Oncol 1998; 25:677–696.PubMedGoogle Scholar
  61. 61.
    Hodge JW, Schlom J. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res 1999; 59:5106–5111.PubMedGoogle Scholar
  62. 62.
    Sabzevari H, Kantor J, Jaigirdar A, et al. Acquisition of CD80 (B7–1) by T cells. J Immunol 2001; 166:2505–2513.PubMedGoogle Scholar
  63. 63.
    Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29:371–380.PubMedCrossRefGoogle Scholar
  64. 64.
    Tjoa BA, Erickson SJ, Bowes VA, et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997;32:272–278.PubMedCrossRefGoogle Scholar
  65. 65.
    Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36:39–44.PubMedCrossRefGoogle Scholar
  66. 66.
    Simmons SJ, Tjoa BA, Rogers M, et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999; 39:291–297.PubMedCrossRefGoogle Scholar
  67. 67.
    Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999; 40:125–129.PubMedCrossRefGoogle Scholar
  68. 68.
    Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000; 60:829–833.PubMedGoogle Scholar
  69. 69.
    Salgaller ML. Peptides in prostate cancer. In: Kast WM, ed. Peptide-based cancer vaccines. Georgetown, TX: Landes Bioscience, 2000; 10:155–171.Google Scholar
  70. 70.
    Peshwa MV, Benike C, Dupuis M, et al. Generation of primary peptide-specific CD8+ cytotoxic Tlymphocytes in vitro using allogeneic dendritic cells. Cell Transplant 1998; 7:1–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization-implications for immunotherapy of prostate cancer. J Immunol 1997; 159:3113–3117.PubMedGoogle Scholar
  72. 72.
    Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894–3903.PubMedGoogle Scholar
  73. 73.
    Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001; 167:7150–7156.PubMedGoogle Scholar
  74. 74.
    Heiser A, Maurice MA, Yancey DR, et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 2001; 166:2953–2960.PubMedGoogle Scholar
  75. 75.
    Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109:409–417.PubMedGoogle Scholar
  76. 76.
    Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 2000; 38:208–217.PubMedCrossRefGoogle Scholar
  77. 77.
    Mincheff M, Altankova I, Zoubak S, et al. In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer-changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Crit Rev Oncol Hematol 2001; 39:125–132.PubMedCrossRefGoogle Scholar
  78. 78.
    Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988; 263:12820–12823.PubMedGoogle Scholar
  79. 79.
    Fung PY, Longenecker BM. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res 1991; 51:1170–1176.PubMedGoogle Scholar
  80. 80.
    Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995; 129:255–265.PubMedCrossRefGoogle Scholar
  81. 81.
    Slovin SF, Livingston P, Keeperman K, et al. Targeted therapy in prostate cancer: vaccination with a glycoprotein, MUC-1-KLH-Q521 peptide conjugate. J Urol 1997; 157:160–169.CrossRefGoogle Scholar
  82. 82.
    Slovin SF, Kelly WK, Scher HI. Immunological approaches for the treatment of prostate cancer. Sem Urol Oncol 1998; 16:53–59.Google Scholar
  83. 83.
    Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998; 4:295–302.PubMedGoogle Scholar
  84. 84.
    Wang ZG, Williams LJ, Zhang XF, et al. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Proc Natl Acad Sci USA 2000; 97:2719–2724.PubMedCrossRefGoogle Scholar
  85. 85.
    Slovin SF, Ragupathi G, Israel R. Ganglioside vaccines in relapsed prostate cancer (PC): experience with GM2-KLH conjugate plus the immunologic adjuvant, Q521-A trial comparing Q521 doses. Proc Am Soc Clin Oncol 1999: 316a, abstr 1214.Google Scholar
  86. 86.
    Slovin SF. Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity. Hematol Oncol Clin North Am 2001; 15:477–496.PubMedCrossRefGoogle Scholar
  87. 87.
    Salgaller ML. Prostate cancer immunotherapy at the dawn of the new millennium. Expert Opin Investig Drugs 2000; 9:1217–1229.PubMedCrossRefGoogle Scholar
  88. 88.
    Hwang LC, Fein S, Levitsky H, Nelson WG. Prostate cancer vaccines: current status. Semin Oncol 1999; 26:192–201.PubMedGoogle Scholar
  89. 89.
    Holmes EH. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs 2001; 10:511–519.PubMedCrossRefGoogle Scholar
  90. 90.
    Israeli RS, Powell CT, Fair WR, Heston WDW. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53:227–230.PubMedGoogle Scholar
  91. 91.
    Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3:81–85.PubMedGoogle Scholar
  92. 92.
    Tino WT, Huber MJ, Lake TP, Greene TG, Murphy GP, Holmes EH. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA). Hybridoma 2000; 19:249–257.PubMedCrossRefGoogle Scholar
  93. 93.
    Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11–05. Cancer Res 1990; 50:6423–6429.PubMedGoogle Scholar
  94. 94.
    Lange PH. PROSTASCINT scan for staging prostate cancer. Urology 2001; 57:402–406.PubMedCrossRefGoogle Scholar
  95. 95.
    McDevitt MR, Barendswaard E, Ma D, et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000; 60:6095–6100.PubMedGoogle Scholar
  96. 96.
    Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999; 5:2674–2681.PubMedGoogle Scholar
  97. 97.
    Arap W, Haedicke W, Bernasconi M, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 2002; 99:1527–1531.PubMedCrossRefGoogle Scholar
  98. 98.
    Sheer DG, Schlom J, Cooper HL. Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res 1988; 48:6811–6818.PubMedGoogle Scholar
  99. 99.
    Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994; 35:1017–1022.PubMedGoogle Scholar
  100. 100.
    Slovin SF, Scher HI, Divgi CR, et al. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 1998; 4:643–651.PubMedGoogle Scholar
  101. 101.
    Meredith RF, Khazaeli MB, Macey DJ, et al. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 1999; 5(10 Suppl):3254s-3258s.Google Scholar
  102. 102.
    Staerz UD, Bevan MJ. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci USA 1986; 83:1453–1457.PubMedCrossRefGoogle Scholar
  103. 103.
    Bauer S, Renner C, Juwana JP, et al. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer Res 1999; 59:1961–1965.PubMedGoogle Scholar
  104. 104.
    Helfrich W, Kroesen BJ, Roovers RC, et al. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int J Cancer 1998; 76:232–239.PubMedCrossRefGoogle Scholar
  105. 105.
    Havranek EG, Whelan MA, Greenhalgh R, Dalgleish AG, Pandha H. Advances in prostate cancer immunotherapy. Surg Oncol 2002; 11:35–45.PubMedCrossRefGoogle Scholar
  106. 106.
    Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 1996; 93:7855–7860.PubMedCrossRefGoogle Scholar
  107. 107.
    Schwaab T, Lewis LD, Bole BF, et al. Phase I pilot trial of the bispecific antibody MDXH210 (antiFcgammaRI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu. J Immunother 2001; 24:79–87.PubMedCrossRefGoogle Scholar
  108. 108.
    James ND, Atherton PJ, Jones J, et al. A phase II study of the bispecific antibody MDX-H210 (antiHER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. Br J Cancer 2001; 85:152–156.PubMedCrossRefGoogle Scholar
  109. 109.
    Webb SR, Sprent J. Induction of neonatal tolerance to Misa antigens by CD8+ T cells. Science 1990; 248:1643–1646.PubMedCrossRefGoogle Scholar
  110. 110.
    Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993; 11:729–766.PubMedCrossRefGoogle Scholar
  111. 111.
    Hoon DS, Yuzuki D, Hayashida M, Morton DL. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 1995; 154:730–737.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Boris Minev
  • Michael L. Salgaller

There are no affiliations available

Personalised recommendations